231 related articles for article (PubMed ID: 31624102)
1. A Somatostatin Receptor Subtype-3 (SST
Vázquez-Borrego MC; Gupta V; Ibáñez-Costa A; Gahete MD; Venegas-Moreno E; Toledano-Delgado Á; Cano DA; Blanco-Acevedo C; Ortega-Salas R; Japón MA; Barrera-Martín A; Vasiljevic A; Hill J; Zhang S; Halem H; Solivera J; Raverot G; Gálvez MA; Soto-Moreno A; Paez-Pereda M; Culler MD; Castaño JP; Luque RM
Clin Cancer Res; 2020 Feb; 26(4):957-969. PubMed ID: 31624102
[TBL] [Abstract][Full Text] [Related]
2. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
[TBL] [Abstract][Full Text] [Related]
3. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
[TBL] [Abstract][Full Text] [Related]
4. Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation.
Ben-Shlomo A; Pichurin O; Barshop NJ; Wawrowsky KA; Taylor J; Culler MD; Chesnokova V; Liu NA; Melmed S
Mol Endocrinol; 2007 Oct; 21(10):2565-78. PubMed ID: 17609435
[TBL] [Abstract][Full Text] [Related]
5. Statins Directly Regulate Pituitary Cell Function and Exert Antitumor Effects in Pituitary Tumors.
Vázquez-Borrego MC; Fuentes-Fayos AC; Herrera-Martínez AD; Venegas-Moreno E; L-López F; Fanciulli A; Moreno-Moreno P; Alhambra-Expósito MR; Barrera-Martín A; Dios E; Blanco-Acevedo C; Solivera J; Granata R; Kineman RD; Gahete MD; Soto-Moreno A; Gálvez-Moreno MA; Castaño JP; Luque RM
Neuroendocrinology; 2020; 110(11-12):1028-1041. PubMed ID: 31940630
[TBL] [Abstract][Full Text] [Related]
6. Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms.
Gatto F; Barbieri F; Arvigo M; Thellung S; Amarù J; Albertelli M; Ferone D; Florio T
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412614
[TBL] [Abstract][Full Text] [Related]
7. Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors.
Feelders RA; de Herder WW; Neggers SJ; van der Lely AJ; Hofland LJ
Drugs Today (Barc); 2013 Feb; 49(2):89-103. PubMed ID: 23462624
[TBL] [Abstract][Full Text] [Related]
8. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
[TBL] [Abstract][Full Text] [Related]
9. [New medical treatments in pituitary adenomas].
Drutel A; Caron P; Archambeaud F
Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S16-28. PubMed ID: 18954854
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography.
Schaer JC; Waser B; Mengod G; Reubi JC
Int J Cancer; 1997 Mar; 70(5):530-7. PubMed ID: 9052751
[TBL] [Abstract][Full Text] [Related]
11. A New Generation Somatostatin-Dopamine Analogue Exerts Potent Antitumoral Actions on Pituitary Neuroendocrine Tumor Cells.
Vázquez-Borrego MC; L-López F; Gálvez-Moreno MA; Fuentes-Fayos AC; Venegas-Moreno E; Herrera-Martínez AD; Blanco-Acevedo C; Solivera J; Landsman T; Gahete MD; Soto-Moreno A; Culler MD; Castaño JP; Luque RM
Neuroendocrinology; 2020; 110(1-2):70-82. PubMed ID: 31272096
[TBL] [Abstract][Full Text] [Related]
12. The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro.
Gruszka A; Kunert-Radek J; Radek A; Pisarek H; Taylor J; Dong JZ; Culler MD; Pawlikowski M
Life Sci; 2006 Jan; 78(7):689-93. PubMed ID: 16115652
[TBL] [Abstract][Full Text] [Related]
13. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
Cescato R; Schulz S; Waser B; Eltschinger V; Rivier JE; Wester HJ; Culler M; Ginj M; Liu Q; Schonbrunn A; Reubi JC
J Nucl Med; 2006 Mar; 47(3):502-11. PubMed ID: 16513620
[TBL] [Abstract][Full Text] [Related]
14. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.
Ben-Shlomo A; Schmid H; Wawrowsky K; Pichurin O; Hubina E; Chesnokova V; Liu NA; Culler M; Melmed S
J Clin Endocrinol Metab; 2009 Nov; 94(11):4342-50. PubMed ID: 19820006
[TBL] [Abstract][Full Text] [Related]
15. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
16. Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms.
Vázquez-Borrego MC; Fuentes-Fayos AC; Herrera-Martínez AD; L-López F; Ibáñez-Costa A; Moreno-Moreno P; Alhambra-Expósito MR; Barrera-Martín A; Blanco-Acevedo C; Dios E; Venegas-Moreno E; Solivera J; Gahete MD; Soto-Moreno A; Gálvez-Moreno MA; Castaño JP; Luque RM
J Clin Endocrinol Metab; 2019 Aug; 104(8):3501-3513. PubMed ID: 30860580
[TBL] [Abstract][Full Text] [Related]
17. Effect of 17beta-estradiol on somatostatin receptor expression and inhibitory effects on growth hormone and prolactin release in rat pituitary cell cultures.
Djordjijevic D; Zhang J; Priam M; Viollet C; Gourdji D; Kordon C; Epelbaum J
Endocrinology; 1998 May; 139(5):2272-7. PubMed ID: 9564833
[TBL] [Abstract][Full Text] [Related]
18. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
Saveanu A; Jaquet P; Brue T; Barlier A
Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
[TBL] [Abstract][Full Text] [Related]
19. Dopamine receptor type 2 (DRD2) and somatostatin receptor type 2 (SSTR2) agonists are effective in inhibiting proliferation of progenitor/stem-like cells isolated from nonfunctioning pituitary tumors.
Peverelli E; Giardino E; Treppiedi D; Meregalli M; Belicchi M; Vaira V; Corbetta S; Verdelli C; Verrua E; Serban AL; Locatelli M; Carrabba G; Gaudenzi G; Malchiodi E; Cassinelli L; Lania AG; Ferrero S; Bosari S; Vitale G; Torrente Y; Spada A; Mantovani G
Int J Cancer; 2017 Apr; 140(8):1870-1880. PubMed ID: 28120505
[TBL] [Abstract][Full Text] [Related]
20. Disulfiram mediated anti-tumour effect in pituitary neuroendocrine tumours by inducing cuproptosis.
Huang N; Feng Y; Liu Y; Zhang Y; Liu L; Zhang B; Zhang T; Su Z; Xue L; Wu ZB
Int Immunopharmacol; 2024 Jun; 134():112159. PubMed ID: 38692018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
